Literature DB >> 29766467

Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Toshikazu Ozeki1,2, Masashi Tsuji3, Junichiro Yamamoto3, Chisato Shigematsu3, Shoichi Maruyama4.   

Abstract

TAFRO syndrome represents a characteristic constellation of symptoms comprising Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, and Organomegaly, and is considered to be a clinicopathologic variant of idiopathic multicentric Castleman disease. A 51-year-old woman was admitted to the hospital complaining of abdominal distension. Findings on physical examination were indicative of anasarca. Computed tomography revealed mild splenomegaly, pericardial effusion, pleural effusion, ascites, and paraaortic lymphadenopathy. Blood tests showed thrombocytopenia, and urinalysis demonstrated hematuria, proteinuria, and worsening renal function. Kidney biopsy was performed and revealed thrombotic microangiopathy-like lesions with global sclerosis of 1 of the 16 glomeruli on light microscopy. The remaining glomeruli had a distinct lobular pattern, with mesangiolysis, double contours of the glomerular basement membranes, and marked endothelial swelling. Immunofluorescence studies for IgG, IgM, IgA, C1q, C3, C4, κ-light chains, and λ-light chains were indeterminate. Electron microscopy showed marked endothelial swelling. We made a diagnosis of TAFRO syndrome and started steroid treatment, following which her symptoms gradually improved. There are few reports describing renal pathology in a patient with TAFRO syndrome.

Entities:  

Keywords:  Renal pathology; TAFRO syndrome; Thrombotic microangiopathy

Mesh:

Substances:

Year:  2018        PMID: 29766467      PMCID: PMC6181886          DOI: 10.1007/s13730-018-0338-x

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  12 in total

1.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly].

Authors:  Kazue Takai; Koji Nikkuni; Hiroyuki Shibuya; Hideki Hashidate
Journal:  Rinsho Ketsueki       Date:  2010-05

2.  Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report.

Authors:  Morihiro Inoue; Mayuka Ankou; Jiang Hua; Yasunobu Iwaki; Masao Hagihara; Yasunori Ota
Journal:  J Clin Exp Hematop       Date:  2013

3.  Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?

Authors:  Yasufumi Masaki; Akio Nakajima; Haruka Iwao; Nozomu Kurose; Tomomi Sato; Takuji Nakamura; Miyuki Miki; Tomoyuki Sakai; Takafumi Kawanami; Toshioki Sawaki; Yoshimasa Fujita; Masao Tanaka; Toshihiro Fukushima; Toshiro Okazaki; Hisanori Umehara
Journal:  J Clin Exp Hematop       Date:  2013

4.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

5.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

6.  Renal involvement in a large cohort of Chinese patients with Castleman disease.

Authors:  Damin Xu; Jicheng Lv; Yujun Dong; Suxia Wang; Tao Su; Fude Zhou; Wanzhong Zou; Minghui Zhao; Hong Zhang
Journal:  Nephrol Dial Transplant       Date:  2011-05-19       Impact factor: 5.992

7.  Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.

Authors:  Hervé Sartelet; Olivier Toupance; Marianne Lorenzato; Fouad Fadel; Laure Hélène Noel; Eymeric Lagonotte; Philippe Birembaut; Jacques Chanard; Philippe Rieu
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

8.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

9.  A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.

Authors:  Fabio Freire José; Lucila Nassif Kerbauy; Guilherme Fleury Perini; Danielle Isadora Blumenschein; Denise da Cunha Pasqualin; Denise Maria Avancini Costa Malheiros; Guilherme de Carvalho Campos Neto; Fabio Pires de Souza Santos; Ronaldo Piovesan; Nelson Hamerschlak
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  A rare case of renal thrombotic microangiopathy associated with Castleman's disease.

Authors:  Anubha Mutneja; L Nicholas Cossey; Helen Liapis; Ying Maggie Chen
Journal:  BMC Nephrol       Date:  2017-02-10       Impact factor: 2.388

View more
  7 in total

1.  Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.

Authors:  Hirotaka Saito; Kenichi Tanaka; Momoko Fujiwara; Tsuyoshi Iwasaki; Tokutaro Numata; Akira Oda; Makoto Kanno; Mizuko Tanaka; Masaaki Eiro; Mamoru Satoh; Junichiro James Kazama
Journal:  CEN Case Rep       Date:  2019-05-10

2.  The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome.

Authors:  Hiroki Mizuno; Naoki Sawa; Shun Watanabe; Daisuke Ikuma; Akinari Sekine; Masahiro Kawada; Masayuki Yamanouchi; Eiko Hasegawa; Tatsuya Suwabe; Junichi Hoshino; Kenmei Takaichi; Keiichi Kinowaki; Takeshi Fujii; Kenichi Ohashi; Michio Nagata; Yutaka Yamaguchi; Yoshifumi Ubara
Journal:  Kidney Int Rep       Date:  2020-05-19

3.  Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.

Authors:  Sylvain Raoul Simeni Njonnou; Justine Deuson; Claire Royer-Chardon; Frédéric Alain Vandergheynst; Virginie De Wilde
Journal:  BMJ Case Rep       Date:  2020-06-30

Review 4.  Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.

Authors:  Amélie Leurs; Viviane Gnemmi; Arnaud Lionet; Loïc Renaud; Jean-Baptiste Gibier; Marie-Christine Copin; Eric Hachulla; Pierre-Yves Hatron; David Launay; David Fajgenbaum; Louis Terriou
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 8.786

5.  Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.

Authors:  Qianyun Zhou; Yuanyuan Zhang; Guangping Zhou; Jihong Zhu
Journal:  BMC Nephrol       Date:  2020-11-23       Impact factor: 2.388

Review 6.  Updates on the diagnosis and management of multicentric Castleman disease.

Authors:  Ya-Ju Wu; Kuei-Ying Su
Journal:  Tzu Chi Med J       Date:  2020-07-29

7.  TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.

Authors:  Yoshikuni Nagayama; Mizuki Yamano; Motoka Yagame; Tomoyuki Nariyama; Mikiko Takahashi; Masashi Kawamoto; Katsuyuki Matsui
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.